Edent1fi

EDENT1FI, a pioneering collaborative effort backed by a €22 million grant from the Innovative Health Initiative (IHI), seeks to combat Type 1 Diabetes (T1D) in its pre-clinical stage. This European consortium, comprising 27 partners across 13 countries, aims to identify early T1D indicators in children from the general population. T1D, impacting millions globally, necessitates a paradigm shift in management, as current screening strategies predominantly focus on familial history despite 90% of new cases lacking these links. The project's objectives are ambitious: to screen European children for early-stage T1D, evaluate the impact across diverse health systems, refine biomarkers for better risk assessment, and develop innovative therapeutic strategies. EDENT1FI also emphasizes public and professional education about T1D care advancements. The EDENT1FI consortium has been initiated by - Prof. Chantal Mathieu, of KU Leuven in Belgium - Prof. Mark Peakman, representing Sanofi - Prof. Anette Ziegler, Director of the Institute of Diabetes Research at Helmholtz Munich, German Research Center for Environmental Health - Carmen Hurtado del Pozo, representing Breakthrough T1D The project's €23.5 million budget primarily stems from Horizon Europe, the Leona M. and Harry B. Helmsley Charitable Trust, JDRF, EFPIA, MedTech, and UK Research and Innovation. Patient involvement through a dedicated advisory committee ensures that the project remains aligned with the needs and perspectives of those affected by T1D. For more information, visit EDENT1FI envisions Europe leading the way in preventing T1D in children, aiming to redefine the landscape of diagnosis and care for this condition.